Brief: PYC Therapeutics Holds Pre-IND Meeting With US FDA
06/11/2023 01:51
Nov 6 (Reuters) - PYC Therapeutics Ltd PYC.AX :
* HELD PRE-IND MEETING WITH US FDA AND AGREED ON PROPOSED
PATHWAY
THROUGH CLINICAL TRIALS FOR DRUG CANDIDATE
* ALIGNED WITH US FDA FOR CLINICAL TRIALS OF ITS
INVESTIGATIONAL
DRUG CANDIDATE FOR AUTOSOMAL DOMINANT OPTIC ATROPHY
* EXPECTS TO PROGRESS DRUG CANDIDATE TO HUMAN TRIALS IN 1H
2024
Source text for Eikon: ID:nASX20RVvq
Further company coverage: PYC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PYC Therapeutics
See all newsAustralia's PYC Therapeutics rises on EU orphan drug status
Brief: PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million
Brief: PYC Therapeutics Announces Raising Up To A$653 Million
Brief: PYC Therapeutics Seeks Trading Halt
Brief: PYC Therapeutics Says Rohan Hockings Re-Appointed As Managing Director